Increased levels of copeptin before clinical diagnosis of preelcampsia

Edwina H. Yeung, Aiyi Liu, James L. Mills, Cuilin Zhang, Tuija Männistö, Zhaohui Lu, Michael Y Tsai, Pauline Mendola

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Copeptin, a surrogate biomarker of vasopressin, has been associated with renal function decline and may serve as a useful early biomarker for preeclampsia. We measured serum copeptin using samples collected longitudinally during pregnancy among unaffected controls (n=136) and cases of preeclampsia (n=169), gestational diabetes mellitus (n=92), gestational hypertension (n=101), and preterm birth (n=86) in the Calcium for Preeclampsia Prevention trial (1992-1995). Preeclampsia and gestational hypertension were defined as having a diastolic blood pressure ≥90 mm Hg on 2 occasions with and without proteinuria, respectively. The risk of pregnancy complications associated with copeptin was estimated by logistic regression adjusting for maternal age, race, body mass index, insurance status, marital status, current smoking, and clinical site. Baseline copeptin levels, at mean 16 weeks of gestation, were associated with increased preeclampsia risk (adjusted odds ratios and 95% confidence interval being 1.55 per log unit; 1.03-2.31) when compared with controls (P=0.03). The association was stronger among cases diagnosed before 37 weeks (1.86; 1.08-3.20) than those diagnosed later (1.45; 0.91-2.32). Copeptin levels rose with increasing gestational age in both cases and controls but remained significantly higher among those who were diagnosed with preeclampsia. Differences in levels of copeptin between cases and controls became more apparent closer to time of diagnosis. No significant associations were found for gestational hypertension without proteinuria, gestational diabetes mellitus, or preterm birth without preeclampsia. Copeptin levels are elevated in pregnant women before diagnosis of preeclampsia with elevation specific to this pregnancy complication rather than hypertension alone.

Original languageEnglish (US)
Pages (from-to)1362-1367
Number of pages6
JournalHypertension
Volume64
Issue number6
DOIs
StatePublished - Jan 1 2014

Fingerprint

Pre-Eclampsia
Pregnancy Induced Hypertension
Gestational Diabetes
Pregnancy Complications
Premature Birth
Proteinuria
Biomarkers
Blood Pressure
Pregnancy
Insurance Coverage
copeptins
Maternal Age
Marital Status
Vasopressins
Gestational Age
Pregnant Women
Body Mass Index
Logistic Models
Smoking
Odds Ratio

Keywords

  • Copeptin
  • Diabetes
  • Gestational
  • Human
  • Hypertension
  • Preeclampsia
  • Pregnancy-induced

Cite this

Yeung, E. H., Liu, A., Mills, J. L., Zhang, C., Männistö, T., Lu, Z., ... Mendola, P. (2014). Increased levels of copeptin before clinical diagnosis of preelcampsia. Hypertension, 64(6), 1362-1367. https://doi.org/10.1161/HYPERTENSIONAHA.114.03762

Increased levels of copeptin before clinical diagnosis of preelcampsia. / Yeung, Edwina H.; Liu, Aiyi; Mills, James L.; Zhang, Cuilin; Männistö, Tuija; Lu, Zhaohui; Tsai, Michael Y; Mendola, Pauline.

In: Hypertension, Vol. 64, No. 6, 01.01.2014, p. 1362-1367.

Research output: Contribution to journalArticle

Yeung, EH, Liu, A, Mills, JL, Zhang, C, Männistö, T, Lu, Z, Tsai, MY & Mendola, P 2014, 'Increased levels of copeptin before clinical diagnosis of preelcampsia', Hypertension, vol. 64, no. 6, pp. 1362-1367. https://doi.org/10.1161/HYPERTENSIONAHA.114.03762
Yeung EH, Liu A, Mills JL, Zhang C, Männistö T, Lu Z et al. Increased levels of copeptin before clinical diagnosis of preelcampsia. Hypertension. 2014 Jan 1;64(6):1362-1367. https://doi.org/10.1161/HYPERTENSIONAHA.114.03762
Yeung, Edwina H. ; Liu, Aiyi ; Mills, James L. ; Zhang, Cuilin ; Männistö, Tuija ; Lu, Zhaohui ; Tsai, Michael Y ; Mendola, Pauline. / Increased levels of copeptin before clinical diagnosis of preelcampsia. In: Hypertension. 2014 ; Vol. 64, No. 6. pp. 1362-1367.
@article{31b4d1a524f5417680d1db4bc35d3452,
title = "Increased levels of copeptin before clinical diagnosis of preelcampsia",
abstract = "Copeptin, a surrogate biomarker of vasopressin, has been associated with renal function decline and may serve as a useful early biomarker for preeclampsia. We measured serum copeptin using samples collected longitudinally during pregnancy among unaffected controls (n=136) and cases of preeclampsia (n=169), gestational diabetes mellitus (n=92), gestational hypertension (n=101), and preterm birth (n=86) in the Calcium for Preeclampsia Prevention trial (1992-1995). Preeclampsia and gestational hypertension were defined as having a diastolic blood pressure ≥90 mm Hg on 2 occasions with and without proteinuria, respectively. The risk of pregnancy complications associated with copeptin was estimated by logistic regression adjusting for maternal age, race, body mass index, insurance status, marital status, current smoking, and clinical site. Baseline copeptin levels, at mean 16 weeks of gestation, were associated with increased preeclampsia risk (adjusted odds ratios and 95{\%} confidence interval being 1.55 per log unit; 1.03-2.31) when compared with controls (P=0.03). The association was stronger among cases diagnosed before 37 weeks (1.86; 1.08-3.20) than those diagnosed later (1.45; 0.91-2.32). Copeptin levels rose with increasing gestational age in both cases and controls but remained significantly higher among those who were diagnosed with preeclampsia. Differences in levels of copeptin between cases and controls became more apparent closer to time of diagnosis. No significant associations were found for gestational hypertension without proteinuria, gestational diabetes mellitus, or preterm birth without preeclampsia. Copeptin levels are elevated in pregnant women before diagnosis of preeclampsia with elevation specific to this pregnancy complication rather than hypertension alone.",
keywords = "Copeptin, Diabetes, Gestational, Human, Hypertension, Preeclampsia, Pregnancy-induced",
author = "Yeung, {Edwina H.} and Aiyi Liu and Mills, {James L.} and Cuilin Zhang and Tuija M{\"a}nnist{\"o} and Zhaohui Lu and Tsai, {Michael Y} and Pauline Mendola",
year = "2014",
month = "1",
day = "1",
doi = "10.1161/HYPERTENSIONAHA.114.03762",
language = "English (US)",
volume = "64",
pages = "1362--1367",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Increased levels of copeptin before clinical diagnosis of preelcampsia

AU - Yeung, Edwina H.

AU - Liu, Aiyi

AU - Mills, James L.

AU - Zhang, Cuilin

AU - Männistö, Tuija

AU - Lu, Zhaohui

AU - Tsai, Michael Y

AU - Mendola, Pauline

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Copeptin, a surrogate biomarker of vasopressin, has been associated with renal function decline and may serve as a useful early biomarker for preeclampsia. We measured serum copeptin using samples collected longitudinally during pregnancy among unaffected controls (n=136) and cases of preeclampsia (n=169), gestational diabetes mellitus (n=92), gestational hypertension (n=101), and preterm birth (n=86) in the Calcium for Preeclampsia Prevention trial (1992-1995). Preeclampsia and gestational hypertension were defined as having a diastolic blood pressure ≥90 mm Hg on 2 occasions with and without proteinuria, respectively. The risk of pregnancy complications associated with copeptin was estimated by logistic regression adjusting for maternal age, race, body mass index, insurance status, marital status, current smoking, and clinical site. Baseline copeptin levels, at mean 16 weeks of gestation, were associated with increased preeclampsia risk (adjusted odds ratios and 95% confidence interval being 1.55 per log unit; 1.03-2.31) when compared with controls (P=0.03). The association was stronger among cases diagnosed before 37 weeks (1.86; 1.08-3.20) than those diagnosed later (1.45; 0.91-2.32). Copeptin levels rose with increasing gestational age in both cases and controls but remained significantly higher among those who were diagnosed with preeclampsia. Differences in levels of copeptin between cases and controls became more apparent closer to time of diagnosis. No significant associations were found for gestational hypertension without proteinuria, gestational diabetes mellitus, or preterm birth without preeclampsia. Copeptin levels are elevated in pregnant women before diagnosis of preeclampsia with elevation specific to this pregnancy complication rather than hypertension alone.

AB - Copeptin, a surrogate biomarker of vasopressin, has been associated with renal function decline and may serve as a useful early biomarker for preeclampsia. We measured serum copeptin using samples collected longitudinally during pregnancy among unaffected controls (n=136) and cases of preeclampsia (n=169), gestational diabetes mellitus (n=92), gestational hypertension (n=101), and preterm birth (n=86) in the Calcium for Preeclampsia Prevention trial (1992-1995). Preeclampsia and gestational hypertension were defined as having a diastolic blood pressure ≥90 mm Hg on 2 occasions with and without proteinuria, respectively. The risk of pregnancy complications associated with copeptin was estimated by logistic regression adjusting for maternal age, race, body mass index, insurance status, marital status, current smoking, and clinical site. Baseline copeptin levels, at mean 16 weeks of gestation, were associated with increased preeclampsia risk (adjusted odds ratios and 95% confidence interval being 1.55 per log unit; 1.03-2.31) when compared with controls (P=0.03). The association was stronger among cases diagnosed before 37 weeks (1.86; 1.08-3.20) than those diagnosed later (1.45; 0.91-2.32). Copeptin levels rose with increasing gestational age in both cases and controls but remained significantly higher among those who were diagnosed with preeclampsia. Differences in levels of copeptin between cases and controls became more apparent closer to time of diagnosis. No significant associations were found for gestational hypertension without proteinuria, gestational diabetes mellitus, or preterm birth without preeclampsia. Copeptin levels are elevated in pregnant women before diagnosis of preeclampsia with elevation specific to this pregnancy complication rather than hypertension alone.

KW - Copeptin

KW - Diabetes

KW - Gestational

KW - Human

KW - Hypertension

KW - Preeclampsia

KW - Pregnancy-induced

UR - http://www.scopus.com/inward/record.url?scp=84922480094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922480094&partnerID=8YFLogxK

U2 - 10.1161/HYPERTENSIONAHA.114.03762

DO - 10.1161/HYPERTENSIONAHA.114.03762

M3 - Article

VL - 64

SP - 1362

EP - 1367

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 6

ER -